Roles in and barriers to metabolic screening for people taking antipsychotic medications: A survey of psychiatrists

Schizophrenia Research

Volumn 143, Issue 2-3, 2013, Pages 395-396

  Parameswaran, S G ^a   Chang, C ^b,c   Swenson, A K ^c   Shumway, M ^c   Olfson, M ^d   Mangurian, C V ^c  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Robert Wood Johnson Clinical Scholars Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

BIPOLAR DISORDER; CLINICAL PRACTICE; DISEASE SEVERITY; FOLLOW UP; HEALTH SURVEY; HUMAN; LETTER; MENTAL DISEASE; METABOLIC REGULATION; PATIENT CARE; PATIENT MONITORING; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOEDUCATION; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MASS SCREENING; METABOLIC DISEASES; MIDDLE AGED; PSYCHIATRY; RISK FACTORS;

EID: 84872367431     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.08.031     Document Type: Letter

References (10)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27(2):596-601.
2. Arbuckle M.R., Gameroff M.J., Marcus S.C., West J.C., Wilk J., Olfson M. Psychiatric opinion and antipsychotic selection in the management of schizophrenia. Psychiatr. Serv. 2008, 59(5):561-565.
3. Buckley P.F., Miller D.D., Singer B., Arena J., Stirewalt E.M. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr. Res. 2005, 79(2-3):281-288.
4. Daumit G.L., Goff D.C., Meyer J.M., Davis V.G., Nasrallah H.A., McEvoy J.P., Rosenheck R., Davis S.M., Hsiao J.K., Stroup T.S., Lieberman J.A. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr. Res. 2008, 105(1-3):175-187.
5. Kreyenbuhl J., Marcus S.C., West J.C., Wilk J., Olfson M. Adding or switching antipsychotic medications in treatment-refractory schizophrenia. Psychiatr. Serv. 2007, 58(7):983-990.
6. Morrato E.H., Druss B., Hartung D.M., Valuck R.J., Allen R., Campagna E., Newcomer J.W. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch. Gen. Psychiatry 2010, 67(1):17-24.
7. Nasrallah H.A., Meyer J.M., Goff D.C., McEvoy J.P., Davis S.M., Stroup T.S., Lieberman J.A. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr. Res. 2006, 86(1-3):15-22.
8. Newcomer J.W., Nasrallah H.A., Loebel A.D. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J. Clin. Psychopharmacol. 2004, 24(5 Suppl. 1):S1-S6.
9. Olfson M., Marcus S.C., Wilk J., West J.C. Awareness of illness and nonadherence to antipsychotic medications among persons with schizophrenia. Psychiatr. Serv. 2006, 57(2):205-211.
10. Parks J., Radke A.Q., Mazade N.A. Measurement of Health Status for People with Serious Mental Illness, National Association of State Mental Health Program Directors, 16th technical report 2008.